# EDGAR Filing Document

**Accession Number:** 0000876378
**File Stem:** 0001437749-23-003916
**Filing Date:** 2023-2
**Character Count:** 16488
**Document Hash:** d028b4bc904d63216d844d169acf8e51
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-003916.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001437749-23-003916

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 81

**CONFORMED PERIOD OF REPORT**: 20230221

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASENSUS SURGICAL, INC.
- **CENTRAL INDEX KEY:** 0000876378
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 112962080
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19437
- **FILM NUMBER:** 23646151

**BUSINESS ADDRESS:**
- **STREET 1:** 1 TW ALEXANDER DRIVE
- **STREET 2:** SUITE 160
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-765-8400

**MAIL ADDRESS:**
- **STREET 1:** 1 TW ALEXANDER DRIVE
- **STREET 2:** SUITE 160
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRANSENTERIX, INC.
- **DATE OF NAME CHANGE:** 20190712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRANSENTERIX INC.
- **DATE OF NAME CHANGE:** 20131210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SafeStitch Medical, Inc.
- **DATE OF NAME CHANGE:** 20080211

asxc20230216_8k.htm

------

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**_________________**

**FORM **8-K**

**_________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

 **Securities Exchange Act of 1934**

**February 21, 2023**

 **Date of Report (date of earliest event reported)**

**_________________**

Asensus Surgical, Inc.

**(Exact name of Registrant as specified in its charter)**

**_________________**

---

| | | |
|:---|:---|:---|
| **Delaware**<br> **(State or other jurisdiction of**<br> **incorporation or organization)** | **0-19437**<br> **(Commission** <br> **File Number)** | **11-2962080**<br> **(I.R.S. Employer**<br> **Identification Number)** |

---

**1 TW Alexander Drive, Suite 160**

**Durham, **NC 27703**

 **(Address of principal executive offices)**

**919-**765-8400**

 **(Registrant**'**s telephone number, including area code)**

**Not Applicable**

 **(Former name or former address, if changed since last report)**

**_________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| **Common Stock**<br> **$0.001 par value per share** | **ASXC** | **NYSE American** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure**

On February 21, 2023, Asensus Surgical, Inc. (the "Company") is hosting an Investor Day to provide a corporate update to investors. The Company notified investors of the date of the Investor Day via press release issued on January 30, 2023. The information provided during such Investor Date is furnished as Exhibit 99.1 to this Form 8-K.

*The information in this Item 7.01 and the Exhibit 99.1 attached hereto shall not be deemed* "*filed*" *for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.*

**Item 8.01 Other Events.**

The Company issued a press release just prior to hosting its Investor Day on February 21, 2023. The press release is attached as Exhibit 99.2 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibit

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description</u> |

---

---

| | |
|:---|:---|
| 99.1 | [Corporate Presentation of Asensus Surgical, Inc. February 21, 2023](ex_478099.htm) |

---

---

| | |
|:---|:---|
| 99.2 | [Press Release of Asensus Surgical, Inc., dated February 21, 2023](ex_478185.htm) |

---

---

| | |
|:---|:---|
| 104 | Cover Page Interactive Data File (formatted in inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **ASENSUS SURGICAL, INC.** |
| Date: February 21, 2023 | /s/ Shameze Rampertab |
|  | Shameze Rampertab <br> Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![c01.jpg](c01.jpg)

------

![c02.jpg](c02.jpg)

------

![c03.jpg](c03.jpg)

------

![c04.jpg](c04.jpg)

------

![c05.jpg](c05.jpg)

------

![c06.jpg](c06.jpg)

------

![c07.jpg](c07.jpg)

------

![c08.jpg](c08.jpg)

------

![c09.jpg](c09.jpg)

------

![c10.jpg](c10.jpg)

------

![c11.jpg](c11.jpg)

------

![c12.jpg](c12.jpg)

------

![c13.jpg](c13.jpg)

------

![c14.jpg](c14.jpg)

------

![c15.jpg](c15.jpg)

------

![c16.jpg](c16.jpg)

------

![c17.jpg](c17.jpg)

------

![c18.jpg](c18.jpg)

------

![c19.jpg](c19.jpg)

------

![c20.jpg](c20.jpg)

------

![c21.jpg](c21.jpg)

------

![c22.jpg](c22.jpg)

------

![c23.jpg](c23.jpg)

------

![c24.jpg](c24.jpg)

------

![c25.jpg](c25.jpg)

------

![c26.jpg](c26.jpg)

------

![c27.jpg](c27.jpg)

------

![c28.jpg](c28.jpg)

------

![c29.jpg](c29.jpg)

------

![c30.jpg](c30.jpg)

------

![c31.jpg](c31.jpg)

------

![c32.jpg](c32.jpg)

------

![c33.jpg](c33.jpg)

------

![c34.jpg](c34.jpg)

------

![c35.jpg](c35.jpg)

------

![c36.jpg](c36.jpg)

------

![c37.jpg](c37.jpg)

------

![c38.jpg](c38.jpg)

------

![c39.jpg](c39.jpg)

------

![c40.jpg](c40.jpg)

------

![c41.jpg](c41.jpg)

------

![c42.jpg](c42.jpg)

------

![c43.jpg](c43.jpg)

------

![c44.jpg](c44.jpg)

------

![c45.jpg](c45.jpg)

------

![c46.jpg](c46.jpg)

------

![c47.jpg](c47.jpg)

------

![c48.jpg](c48.jpg)

------

![c49.jpg](c49.jpg)

------

![c50.jpg](c50.jpg)

------

![c51.jpg](c51.jpg)

------

![c52.jpg](c52.jpg)

------

![c53.jpg](c53.jpg)

------

![c54.jpg](c54.jpg)

------

![c55.jpg](c55.jpg)

------

![c56.jpg](c56.jpg)

------

![c57.jpg](c57.jpg)

------

![c58.jpg](c58.jpg)

------

![c59.jpg](c59.jpg)

------

![c60.jpg](c60.jpg)

------

![c61.jpg](c61.jpg)

------

![c62.jpg](c62.jpg)

------

![c63.jpg](c63.jpg)

------

![c64.jpg](c64.jpg)

------

![c65.jpg](c65.jpg)

## Exhibit 99.2

**Exhibit 99.2**

**Asensus Surgical Provides Corporate Update**

RESEARCH TRIANGLE PARK, N.C.--(GLOBE NEWSWIRE)--February 21, 2023-- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, is providing this corporate update in conjunction with its previously announced Investor Day, which will be hosted today, beginning at 11:30am EST.

"Our vision is to revolutionize the way surgery is performed and ultimately the way patients are treated. To date, we have made tremendous progress evolving robotically-assisted surgery into Digital Laparoscopy with the combination of our Senhance® Surgical System and the intelligent capabilities of our Intelligent Surgical Unit™(ISU™). However, we expect more from a surgical solution," said Anthony Fernando, President and Chief Executive Officer of Asensus. "We have first hand knowledge, shaped by thousands of real-world procedures and years of interactions with surgeons and hospitals, of what the market needs, which is much more than just a robot. The best solution will materially reduce surgical variability and deliver improved outcomes. We are working to deliver that solution, a new era of surgery called Performance-Guided Surgery, the foundation of which will be our new LUNA™ Surgical System and the clinical intelligence capabilities provided to surgeons through the ongoing development of the ISU."

Based on its clinical and commercial experience to date, the Company is introducing an integrated Digital Surgery solution comprising a next generation surgical platform and instruments, real-time intraoperative clinical intelligence and a secure cloud platform to apply machine learning to deliver clinical insights. This Digital Surgery solution will enable the Company's vision of Performance-Guided Surgery.

**LUNA, the Company**'**s Next Generation Digital Surgery Platform**

Designed based on the feedback received from over 10,000 digital laparoscopic procedures performed with the Senhance System, the LUNA Surgical System is the Company's next generation digital surgery platform. Through a combination of advanced minimally invasive instrumentation, the first ever digital interface between the surgeon and the console, and industry-leading clinical intelligence tools, we believe LUNA is poised to revolutionize the way surgery is performed.

------

The LUNA Surgical System is under development, and not currently available for use.

![ex_478185img001.jpg](ex_478185img001.jpg)

*The LUNA Surgical System is Asensus*' *next generation digital surgery platform that is poised to revolutionize the way surgery is performed*.

**New Intelligent Surgical Unit Capabilities Announced**

The Company is announcing incremental features sets which are now under development:

● An Analytical Feature Set, which includes pre-operative surgical planning that will allow surgeons to map out and plan for specific surgical actions intraoperatively using the ISU's Augmented Intelligence

● A Safety Feature Set, which includes "no fly zone" functionality that will enable the identification and marking of potential hazards during the operation, thereby restricting instruments from entering into defined anatomical structures

● A Training and Education Set, which includes telestration, allowing multiple team members to work together in real-time by annotating, highlighting and drawing on a shared visual display of the surgical field

------

**Cloud Data Architecture and Machine Learning**

Asensus Surgical previously announced that it agreed on a multi-year strategic collaboration with Google Cloud to integrate Google Cloud's secure cloud data architecture and machine learning technologies to further expand the capabilities of the Asensus Surgical's Performance-Guided Surgery framework enabled through the ISU. Google's secure cloud data architecture will capture this data and Asensus will enable customer access portals and performance dashboards for surgeons and hospitals. Google's machine learning technologies will be utilized to analyze the data and discern clinical intelligence that can be utilized by surgeons and hospitals in addition to continuously improving the software in the ISU to provide better intra-operative clinical insight. This collaboration to better capture clinical performance data and apply Augmented Intelligence capabilities is expected to provide clinical insight and drive superior outcomes for patients.

**KARL STORZ Collaboration Agreement**

The Company previously announced that it had entered into a Memorandum of Understanding with KARL STORZ VentureONE Pte. Ltd. (KARL STORZ), a new wholly owned subsidiary of KARL STORZ SE & Co. KG, a global leader in the medical technologies industry, especially in the area of endoscopes, medical instruments, and devices that offers state-of-the-art technology for minimally invasive procedures in virtually all surgical specialties. As part of this agreement, KARL STORZ intends to market and sell Asensus' Intelligent Surgical Unit as a standalone device together with their IMAGE1 S™ Imaging system and OR1™ integration solution. The companies also intend to work together on the integration of the ISU into KARL STORZ's laparoscopic vision systems and jointly collaborate on developing next-generation instrumentation to be used with Asensus and KARL STORZ surgical platforms. As a solution-oriented and innovative partner, KARL STORZ is in close collaboration with surgeons and health care partners around the globe to enable them to perform at their very best every day to improve patients' lives. Upon finalization of the definitive agreements, the ISU's will bring its advanced Augmented Intelligence capabilities to operating rooms around the world.

**February 2023 Investor Day**

The Company is hosting an Investor Day today, Tuesday, February 21, 2023 in New York, NY. The event will begin at 11:30 AM EST. A live webcast of the conference presentation will be available online on the investor relations page of the Company's website at <u>https://ir.asensus.com/events-and-presentations</u>. Replays of the webcasts will be archived on the website.

------

**About Asensus Surgical, Inc.**

**Follow Asensus**

Email Alerts: <u>https://ir.asensus.com/email-alerts</u>

LinkedIn: <u>https://www.linkedin.com/company/asensus-surgical-inc</u>

Twitter: <u>https://twitter.com/AsensusSurgical</u>

YouTube: <u>https://www.youtube.com/c/transenterix</u>

Vimeo: <u>https://vimeo.com/asxc</u>

**Forward-Looking Statements**

This press release includes statements relating to Asensus Surgical and its corporate update. These statements and other statements regarding our future plans and goals constitute "forward looking statements'' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Asensus Surgical will be able to successfully develop its LUNA Surgical System, whether Asensus Surgical's Digital solution will enable its vision of Performance-Guided Surgery, whether the LUNA Surgical System will revolutionize the way surgery is performed, whether the incremental features sets under development for the ISU will be successful, whether the collaboration between Asensus Surgical and Google Cloud will be successful and whether definitive agreements will be successfully negotiated and lead to a successful collaboration between Asensus Surgical and Karl Storz. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

------

**INVESTOR CONTACT:**

Mark Klausner or Mike Vallie, 443-213-0499

invest@asensus.com

**MEDIA CONTACT:**

Isabella Rodriguez, 708-833-1572

CG Life

irodriguez@cglife.com